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Sequencing of gene-coding regions (the exome) is increasingly used for studying humandisease, for which copy-number variants (CNVs)
are a critical genetic component. However, detecting copy number from exome sequencing is challenging because of the noncontiguous
nature of the captured exons. This is compounded by the complex relationship between read depth and copy number; this results from
biases in targeted genomic hybridization, sequence factors such as GC content, and batching of samples during collection and
sequencing. We present a statistical tool (exome hidden Markov model [XHMM]) that uses principal-component analysis (PCA) to
normalize exome readdepth andahiddenMarkovmodel (HMM) todiscover exon-resolutionCNVandgenotypevariationacross samples.
We evaluate performance on 90 schizophrenia trios and 1,017 case-control samples. XHMMdetects amedian of two rare (<1%)CNVs per
individual (one deletion and one duplication) and has 79% sensitivity to similarly rare CNVs overlapping three ormore exons discovered
with microarrays. With sensitivity similar to state-of-the-art methods, XHMM achieves higher specificity by assigning quality metrics to
the CNV calls to filter out bad ones, as well as to statistically genotype the discovered CNV in all individuals, yielding a trio call set with
Mendelian-inheritance properties highly consistent with expectation. We also show that XHMM breakpoint quality scores enable
researchers to explicitly search for novel classes of structural variation. For example, we apply XHMM to extract those CNVs that are
highly likely to disrupt (delete or duplicate) only a portion of a gene.Introduction
Copy-number variants (CNVs) have emerged in the last
decade as a category of structural genetic diversity that
plays a key role in human health and common disease.1
A number of studies have implicated deletion and duplica-
tion CNVs in cancer susceptibility, metastasis, gene expres-
sion, and treatment.2 Similarly, rare CNVs are enriched in
individuals with severe neuropsychiatric conditions, such
as autism (MIM 209850), schizophrenia (MIM 181500),
intellectual disability, and epilepsy.3–6 In fact, copy-
number changes are the variants that have the largest
known effect on the risk of schizophrenia possibly as
a result of the constant introduction of de novo germline
mutations.7 However, knowledge regarding the scope of
CNV effects on disease is still incomplete. This results
from the need for additional samples, as well as from
a lack of fine-grained genomic resolution in existing tech-
nologies, such as microarray-based approaches (SNP arrays
or array comparative genomic hybridization [aCGH]), with
which most work on CNV detection has been performed.
Although aCGH has gained resolution over the years, its
widespread use might be limited because of its focus on
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The AmericThe introduction of next-generation-sequencing (NGS)
technology has provided a window into the genome at
base-pair resolution and has the advantage of allowing
simultaneous discovery of single-nucleotide, indel, and
structural (translocation, inversion, and copy-number)
variation. In practice, many recent disease studies have
chosen high-depth targeted exome sequencing, i.e.,
focusing on known coding regions of the genome.8,9 The
key reasons for this are the lower cost as compared to that
of whole-genome sequencing, the expectation from
Mendelian disorders that the exome will be enriched for
disease mutations, and the interpretability of a variant’s
effect on gene product. Such studies are likely to continue
into the foreseeable future because exome sequencing of
many individuals will have more statistical power to detect
disease association than will whole-genome sequencing of
fewer individuals. However, to maximize the impact on
disease, these studies need to integrate the full spectrum
of genetic variation ascertainable by using sequencing
even though this is fraught with difficulty.10
Numerous tools exist for discovering CNVs from array
intensities, and recent work has placed CNV calling on
solid ground for whole-genome sequencing data by
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Figure 1. XHMM Pipeline for Discovery
and Genotyping of CNVs from Exome
Read-Depth Information
The XHMM framework starts with aligned
exome read BAM files to: (1) calculate
depth of coverage (top left panel), (2)
normalize read depth by using principal-
component analysis (PCA) (top right
panel), (3) train and run a hidden Markov
model (HMM) (bottom right panel), and
(4) output CNV calls and genotype quali-
ties for all samples (bottom left panel).of read mate pairs to the reference genome, ‘‘split’’ reads
that span breakpoints, and sequencing depth of coverage,
i.e., ‘‘read depth.’’11 In contrast, because exome sequencing
takes aim at a sparse (~1%) set of noncontiguous genomic
targets (the exons), most CNV breakpoints will not be
sequenced, leaving read depth as the predominant indi-
cator of CNVs. However, the quantitative relationship
between true copy number and depth is distorted by
target- and sample-specific biases in exome hybridization
(‘‘capture’’), PCR amplification, sequencing efficiency,
and in silico readmapping, all of which are in turn affected
by GC content of the targets, target size and sequence
complexity, proximity to segmental duplications, nucleo-
tide-level variation (SNPs), DNA concentration, hybridiza-
tion temperature, experimental sample batching, and the
complex interplay among these and various indeterminate
factors (Figure S1, available online). The resulting differ-
ences are dramatic in that the number of reads varies by
an order of magnitude or more (Figure S2), even for diploid
regions (copy number ¼ 2). Hence, whole-genome read-
depth methods are not applicable to targeted sequencing
if the extra biases are not accounted for.
Previously, researchers tailored CNV methods to tar-
geted sequencing and used read-depth normalization to
account for a small set of predefined factors, including
background depth, GC content, and analysis window
size.12 When ‘‘split’’ read evidence exists, it has been used
for augmenting detection of CNVs,13 as well as other
structural variants, indels, and copy-number-polymor-
phic-processed pseudogenes.14 Cancer studies have af-
forded themselves the use of per-sample case-control
matching (tumor versus normal) to simplify depth normal-
ization.15
To augment the repertoire of tools for ‘‘variation
hunting,’’ we developed XHMM (exome hidden Markov
model, Figure 1), a statistical toolset for detecting exon-598 The American Journal of Human Genetics 91, 597–607, October 5, 2012resolution CNVs from exome
sequence data with a disease-moti-
vated focus on rare (<5%) events
(see Material and Methods). XHMM
extracts copy-number signal from
noisy read depth by leveraging the
large-scale nature of sequencing
projects to discern patterns of read-depth biases. Specifically, we ran a principal-component
analysis (PCA) on the sample-by-target-depth matrix by
‘‘rotating’’ the high-dimensional data to find the main
modes in which depth varies across multiple samples and
targets, and we removed the largest of such effects. This
resulted in rigorous data-driven normalization (Figure S2)
without the requirement of detailed knowledge of the
particular confounders, although we did observe correla-
tion with expected ones such as GC content (Figure S3).
After this, we used a hidden Markov model (HMM) to
discover CNVs spanning adjacent targets, where depletion
or enrichment in normalized read depth implies a deletion
or duplication, respectively. Our model takes into account
genome-wide CNV rates, length, and distance between
exome targets. Next, we derived HMM-based quality scores
that measure the certainty we have regarding a CNV,
its breakpoints, not having a CNV, and other metrics
(see Material and Methods), which we implemented as
a multisample quantitative genotyping module that
estimates which samples show some (or no) evidence of
a CNV discovered in another sample. Thus, XHMM is
uniquely suited to detect de novo CNVs and other events
requiring high-confidence accuracy, e.g., CNVs whose
breakpoints fall within a gene and leave only a partial
segment16 where such ‘‘gene disruptions’’ have been impli-
cated in disease.6,17,18,19
Material and Methods
Primary CNV-Calling Pipeline
We now detail the six steps in the XHMM framework for CNV
detection from exome sequencing data.
Coverage: Per-Sample, Per-Target Depth
To start, XHMM requires sequencing reads aligned to the refer-
ence genome (in a BAM file), for which we use the Picard/
Genome Analysis ToolKit (GATK) NGS data-processing pipeline
implemented at the Broad Institute, as previously described.20 In
brief, the Burrows-Wheeler Aligner (BWA)21 was used for read
mapping and was followed by local realignment around known
indels, marking of PCR duplicates, and base-quality-score recali-
bration. Next, XHMM uses GATK to calculate raw depth-of-
coverage values across the exome. Specifically, at a given genomic
position, the depth of coverage is defined as the number of
sequenced reads aligning to that base (Figure 1, top left), and
a minimum read mapping quality of 20 is required by default.
This quality threshold is intended for the removal of reads that
are spuriously mapped to a target or that have the potential to
equally map to multiple genomic loci (MQ0 reads), but this value
can be changed without grossly affecting results. For each exon
target, the depth-of-coverage values are averaged over its extent,
yielding a raw read-depth matrix of samples by targets (Figure S1);
the value of a matrix entry is the mean number of reads covering
each base in the corresponding target for a particular sequenced
sample.
Filter I: Extreme Targets and Samples
The purpose of this prenormalization step is to ensure relative
homogeneity in the samples and targets and prevent deviant
values from adversely affecting the subsequent PCA. To do this,
XHMM performs an outlier removal step, in which it filters out
targets with extreme GC content (<0.1 or >0.9), targets with
a significant stretch of low-complexity sequence (>10% of target
bases soft masked by RepeatMasker22 in the hg19 human reference
sequence), targets less than 10 bp or larger than 10 kb, or
targets with very low coverage (<103 averaged over all samples)
or very high coverage (>5003) in our experiment. Because the
samples here were sequenced to an average coverage of 100–
1503, we next removed samples with coverage values that
were empirical outliers with respect to the full set of samples—
those with unexpectedly low coverage (<503 averaged over all
targets), high coverage (>2003), or extreme variance (standard
deviation > 120 over all targets). As an example, the read-depth
distributions for individual samples and targets are plotted in
Figure S4. For other studies, we recommend examining the read-
depth distributions and removing appropriate outliers.
PCA Normalization of Read Depth
The read depth of exome sequencing for an exon target is a
function of a number of biochemical properties of the genome,
in addition to experimental and bioinformatic steps including
genomic fragmentation, array hybridization (‘‘capture’’), PCR,23
sequencing,24 and in silico alignment to the reference genome
(‘‘mapping’’).25,26 Direct readout of copy number from depth of
coverage is not possible because of local genomic-context effects
(e.g., GC content,27 repeats, or low-complexity sequence), the
inherent biases in each experimental step, and the dynamic range
of ambient conditions during the handling of different sample
batches.
We thus hypothesized that most of the read-depth variation
within a sample and between targets is in fact dominated by
effects unrelated to and independent of copy number. To
normalize out what is effectively noise when looking for CNV
signal, we applied PCA to find the main sources of confounding,
i.e., orthogonal high-dimensional axes in which the read depth
varies (Figure 1, top right). In detail, we first centered the target
read depths about their means and used the singular value decom-
position (SVD) implementation of PCA on the individual-by-
target read-depth matrix. To better understand the nature of the
systematic biases on target depth, we calculated the correlation
between the top 100 principal components and various signalsThe Americthat we expected to possibly be involved in determining the
read depth of exome sequencing, and we observed the strongest
correlations with sample batch, exome-wide mean sample and
target depths, target GC content, population, and combinations
of these factors (Figure S5). Importantly, some of the highest
components were not apparently correlated with any of these pre-
defined phenomena, yet they clearly were not indicative of CNV
levels. In practice, a scree plot (Figure S6) is often statistically infor-
mative for visually aiding the selection of components with high-
est variance if one looks for an ‘‘elbow’’, i.e., a sharp drop in the
read-depth variance contributed by later principal components,
in the plot.
More formally, to find the high-variance components that are
presumed to explain most of the read-depth variation (due to
systematic biases), XHMM follows the empirical rule of thumb
by calculating the relative variance of each component and
removing the K components with a value of 0.7 / n or higher,28
where n is the number of components (in this case, number of
samples) and 0.7 is a user-tunable XHMM parameter. To remove
these K components, we subtract them out from the matrix of
all samples’ read depths R to obtain the normalized read-depth
matrix R*:
R ¼ R
XK
i¼1
cic
T
i R; (Equation 1)
where ci is the i
th principal component of R to be normalized out of
the depth signal.
As an example, the left panel of Figure S2 demonstrates the large
positional and sample effects of the raw readdepths for 500 samples
in a region of 26 targets across almost 200 kb; the most striking
observation is that each target has a characteristic mean shift of
sequencing coverage. Furthermore, particular samples show con-
sistently higher (or lower) coverage possibly as a result of batch-
ing effects, global extent of sequencing for that sample, or a real
signal of CNVs. The read depths for a number of samples sus-
pected of having duplication events are highlighted in green, but
these CNVs can be directly read off only after normalization (right
panel).
Filter II: Extremely Variable Targets
After the PCA normalization, there were still a number of targets
with extreme variability in normalized depth. Thus, by default,
XHMM filters out targets with a standard deviation of normalized
read depth > 30 in an effort to ensure homogeneity in the input
for the next stage and remove any outliers not normalized in
previous steps. The filtering performed at this stage might need
to be adapted to the features of a particular experiment.
Discovery: Per-Sample CNV Detection with a HMM
In the next step, XHMM discovers CNVs in each sample by using
a HMM algorithm for segmentation of the exome into ‘‘diploid,’’
‘‘deletion,’’ or ‘‘duplication’’ regions, which correspond to average,
below-average, and above-average read depth, respectively. To do
this, XHMM first transforms the PCA-normalized read depths by
using a Z score calculation for each sample separately so that
target-depth values are on a similar scale. These Z scores are used
as input to a 3-state HMM (Figure 1, bottom right) that is concep-
tually similar to that used for whole-genome methods,29 but it
takes into account exome-wide CNV rates and length distribu-
tions, as well as the distance between exome targets (this makes
it more likely to continue a CNV within a single gene than across
distant genes). The underlying homogeneous HMM state-transi-
tion matrix is given in Table 1, where 0 < p < 1 is the exome-
wide CNV rate, q ¼ 1 / T, and T > 0 is the mean number of targetsan Journal of Human Genetics 91, 597–607, October 5, 2012 599
Table 1. Basic HMM Transition Matrix
From Y To/ Deletion Diploid Duplication
Deletion 1  q q 0
Diploid p 1  2p p
Duplication 0 q 1  q
This matrix takes into account the exome-wide CNV rate (p) and the mean
number of targets in a CNV (1 / q).
Table 2. Distance-Dependent HMM Transition Matrix
From Y To/ Deletion Diploid Duplication
Deletion f(1  q) þ
(1  f)p
fq þ (1  f)(1  2p) (1  f)p
Diploid p 1  2p p
Duplication (1  f)p fq þ (1  f)(1  2p) f(1  q) þ
(1  f)p
For two exons located d base pairs apart, this matrix takes into account exome-
wide CNV rate, the mean number of CNV targets (see Table 1), and the atten-
uation of CNV rates at distance d (f ¼ ed/D, where D is the mean distance
between targets in a CNV).in a CNV (geometrically distributed with parameter q). Note that,
for simplicity, this model is symmetric with respect to deletions
(copy number < 2) and duplications (copy number > 2), although
it need not be so. In order to take into account the distance
between targets in the exome (denoted by d), we overlay onto
the matrix in Table 1 a distance-dependent exponential attenua-
tion factor, f ¼ ed/D, where D is the expected distance between
targets in a CNV (in bases). For longer distances between targets
(weighted by 1  f), we want the probability of being in a CNV
to approach that of starting a CNV from a previously diploid state
(middle row). This results in the final nonhomogeneous state-tran-
sition probabilitymatrix for two targets at a distance of d base pairs
(Table 2).
Because we normalize the read-depth values into Z scores, the
read-depth emission probability function is symmetrically taken
to be a normal distribution of variance 1 centered at M, 0,
and þM, for deletion, diploid, and duplication, respectively.
To perform CNV discovery, XHMMmakes copy-number calls by
using the standard HMM Viterbi algorithm, which provides the
most likely copy-number state given all of the sample’s read-depth
data (Figure 1, bottom left) and fixed HMM parameters. To choose
HMM parameters, we used the trio samples to perform a grid
search to find a combination of all parameters minimizing both
the number of putative ‘‘de novo’’ CNVs and the deviation from
a 50% transmission rate. We considered p to be between 104
and 108, T to be between 1 and 6, D to be between 103 and 5 3
105, andM to be between 1 and 6. On the basis of the trio data, we
chose CNV rate p ¼ 108, mean targets per CNV T ¼ 6, mean
within-CNV target distance D ¼ 70,000 (70 kb), and depth Z score
threshold M ¼ 3. These parameters, although by no means the
‘‘optimal’’ ones, are reasonable in nature, and we expect them to
be broadly applicable for similar experimental exome data sets
without significant fine tuning. Importantly, these parameters still
give a liberally large CNV call set that should maximize sensitivity
toward finding almost all CNV calls for which there is sufficient
read-depth signal, whereas we use the quality metrics defined
below to achieve higher specificity.
Genotype: Assign HMM-Based Quality Metrics to All Samples for
Discovered CNVs
After running the per-sample HMM Viterbi algorithm to discover
CNV in each sample, we leveraged the HMM framework to
‘‘genotype’’ each such event across all samples in the data set.
Specifically, we derived metrics from the rich field of HMMs to
calculate posterior probabilities of, for example, having the whole
delineated region as deleted, having some deleted target in the
region, not having any deleted targets at all, or having the break-
point occurring exactly as called in the discovery step. These quan-
tities can be calculated efficiently with the HMM chain structure
and can be used for defining quality scores regarding the event
occurring (or not occurring) in a particular sample. The important600 The American Journal of Human Genetics 91, 597–607, Octoberpoint is that these can be applied to any sample with read-depth
data and not just the sample in which the CNV was originally
discovered.
As a concrete example, let us assume that a deletion was discov-
ered in some sample ranging between targets t1 and t2, and we
would like to genotype this event in a different sample, whose
normalized read-depth Z score and underlying copy-number
vectors we denote by y1:E and x1:E, respectively (E is the number
of exome-wide targets). For simplicity, we denote deletion, diploid,
and duplication states as 1, 2, and 3, respectively.
Now, running the standard HMM forward-backward algorithm
on this sample gives the quantities:
Forward probability of copy number xt at target t:
ftðxtÞ ¼ Pr

y1:t ; xt

Backward probability of copy number xt at target t:
btðxtÞ ¼ Pr

ytþ1:E j xt

Data likelihood:
Pr

y1:E
 ¼
X3
xt¼1
ftðxtÞ$btðxtÞ;c1%t%E:
With HMM theory, it can be shown that the probability of copy-
number sequence xt1 :t2 given the sample’s read depths is
Pr

xt1 :t2 j y1:E
 ¼
ft1

xt1

$
Yt2
t¼t1þ1
Prðxt j xt1Þ$
Yt2
t¼t1þ1
Pr

yt j xt

$bt2

xt2

Pr

y1:E
 ;
where Pr(xt j xt1) and Pr(yt j xt) are the transition and emission
probabilities, respectively, defined above. We thus obtain
Prðxt1 :t2 ¼ 1jy1:EÞ, Prðxt1 :t2 ¼ 2jy1:EÞ, and Prðxt1 :t2 ¼ 3jy1:EÞ as the
probabilities of the sample’s copy-number state being deletion,
diploid, orduplication, respectively, for all targets between t1 and t2.
Another quantity of interest is the probability of the copy
number being restricted to certain categories (in this case, no
duplications):
Pr

xt1 :t2˛f1;2g j y1:E
 ¼ Prxts3; t1%t%t2 j y1:E

¼ Pr

y1:E; xts3; t1%t%t2

Pr

y1:E
 ;
where the denominator is the standard likelihood defined above
and the numerator is a modified likelihood that we calculate by
locally rerunning the forward-backward algorithm with the added5, 2012
Figure 2. Calibration of XHMM CNV
Quality Parameters with 90 Schizophrenia
Trio Samples
We calibrate the XHMM parameters by
considering how the number of rare
CNVs per child (left panel), putative de
novo events (middle panel), and parent-
to-child transmission rates (right panel)
vary as a function of increasingly stringent
quality filtering. Boxes denote the inter-
quartile range over all 90 trios. Horizontal
solid lines indicate the median, and whis-
kers extend to the most extreme data
points at most 1.53 the interquartile range
from the box.constraint that Prðyt jxt ¼ 3Þ ¼ 0;ct1%t%t2 (no duplications
allowed).
Finally, we define the relevant CNV genotyping qualities as:Exact deletion ¼ EQ ¼ PhredPrxt1 :t2 ¼ 1 j y1:E

Some deletion ¼ SQ ¼ PhredPrxt1 :t2˛f1; 2g j y1:E
 Prxt1 :t2 ¼ 2 j y1:E

No deletion ¼ NQ ¼ PhredPrxt1 :t2˛f2; 3g j y1:E

Left deletion breakpoint ¼ LQ ¼ PhredPrxt11 ¼ 2; xt1 ¼ 1 j y1:E

Right deletion breakpoint ¼ RQ ¼ PhredPrxt2 ¼ 1; xt2þ1 ¼ 2 j y1:E

Not Diploid ¼ NDQ ¼ Phred1 Prxt1 :t2 ¼ 2 j y1:E

Diploid ¼ DQ ¼ PhredPrxt1 :t2 ¼ 2 j y1:E

;where given the probability of a particular CNV genotype quantity
c, the Phred-scaled quality of c not being an error is
Phred½PrðcÞ ¼ 10 log10ð1 PrðcÞÞ;
and a higher quality score implies greater probability that the
quantity is supported by the data. Note that it always holds that
SQ R EQ because SQ is the CNV deletion quality based on the
probability that at least one of the targets is deleted, whereas EQ
requires that all targets in the range be most likely deleted.
However, only LQ and RQ explicitly require that the particular
breakpoints at t1 and t2 be highly likely. Note that similar metrics
are of course defined for duplication events.
Applications of Genotype Quality Metrics
When we wish to know whether a particular individual carries the
event in question or a similar event (e.g., any deletion in a region),
we apply the above-defined genotype qualities depending on the
context. For example, we used the trios to calibrate the XHMM
parameters and genotype quality thresholds to enable us to
converge to accurate, yet sensitive, CNV calls by considering the
number of calls, the implied de novo CNV rates, and Mendelian
transmission rates from parent to child (Figure 2). We will denote
by Q a global quality threshold (in this paper, a value of 60 was
ultimately derived from the trio data). We now step through
some typical use cases in which these scores can be applied for
making statistically informed conclusions about the CNV in ques-
tion despite the presence of noise. Note that these metrics can also
be applied in the case of CNV regions defined externally, where
XHMM will use the overlapping targets in a region to calculate
the full list of metrics above.The AmericDe Novo CNV
For a deletion CNV event discovered in a child, we would like to
ask whether the parents have strong evidence for being diploidover the entire span of exon targets (thus implying a de novo dele-
tion). To answer this in the affirmative, we require that SQR Q in
the child and that NQ R Q in each of the parents so that we are
confident that the read depths support at least some deletion
event existing in the child’s exome and not a hint of a deletion
in either parent.
CNV Transmission from Parents
When a CNV is discovered in a parent sample with the HMM
Viterbi step, we want to test whether this was, or was not, trans-
mitted to the child. For this, we require that SQ R Q in this
parent (to be confident in, at least a portion of, the parental
CNV) and require that the child’s genotype qualities satisfy
SQR Q (transmitted) or NQR Q (not transmitted); if the child’s
call does not satisfy either of these criteria, then it is effectively
marked as ‘‘missing’’ and we do not include it in this analysis
because of the uncertainty. The ‘‘missing’’ genotype permits
us to make the important distinction between the absence of a
Viterbi call and actually being confident that a sample is diploid.
Note that we also ensure that NQ R Q in the other parent so
that we know that only one parent could have transmitted this
CNV.
Disruptive CNV
To detect high-quality gene-disrupting CNVs, we use the standard
quality threshold Q to ensure that there is a significant signal
(SQ R Q) of the called CNV. Also, to be certain that at least one
of the breakpoint locations (50 or 30) is of high quality, we require
that LQ R Q0 or RQ R Q0, where Q0 % Q is some more relaxed
threshold (we chose Q0 ¼ Q / 2 ¼ 30 as a reasonable value in this
study). Lastly, we require that the breakpoint with high certainty
actually falls within a gene transcript and not at the edge of
the gene.an Journal of Human Genetics 91, 597–607, October 5, 2012 601
Comparison of Overlapping CNV
Note that a similar approach to that for finding disruptive CNV
could be used for inferring whether overlapping CNVs in two
different individuals are in fact the same event or not. Specifically,
we would require high-quality CNV breakpoints and would
compare their respective locations for the two samples. This test
can be used for investigating the possibilities of recurrent events
that have different mechanisms, have the same mechanism, or
are identical by descent.
Genotyping an Entire Genomic Interval
Finally, for the case of genotyping a sample as being either diploid,
deleted, duplicated, or ‘‘no call’’ over an entire particular region,
XHMM applies one of the four rules below.
1. Call as diploid if DQR Q (and SQdel < Q and SQdup < Q).
2. Call as deletion if EQdelR Q (and NQdel < Q).
3. Call as duplication if EQdupR Q (and NQdup < Q).
4. Otherwise, no call is made (‘‘missing’’ genotype).
Note that these determine the actual hard genotype calls present
in the VCF file output by XHMM; in order to correct for the fact
that DQ and EQ will be strongly correlated with the number
of targets in the region, XHMM chooses Q here on a call-by-call
basis as the minimum EQ in the samples in which this call was
discovered.Focus on Rare Variation
We have optimized XHMM for rare variation (frequency < 0.05)
because of the typical application of exome sequencing for
complex diseases and the fact that common CNVs (copy-number
polymorphisms [CNPs]) do not explain much risk for these
diseases.30 Specifically, the PCA normalization and HMM parame-
ters have been tuned under the assumption that most read-depth
variation at a given locus is due to noise, whereas a CNP would
not fit into this mold. More generally, the user might need to
adjust some of the parameters in the description above in order
to maximize the trade-off between false positives and false nega-
tives. However, under reasonable experimental settings, we expect
the default values noted to give a liberally called (but not too large)
set of CNVs, which can then be easily and effectively filtered
by frequency and with the use of the CNV quality scores output
by XHMM.Exome Data Sets Used
In this work, we adopted the following two neuropsychiatric data
sets (in the context of large schizophrenia studies currently
underway) as a focus for our methods:
d 90 trios (a child with schizophrenia and his or her parents),
which are part of a larger ongoing sequencing effort of over
600 trios from Bulgaria.7
d 1,017 individuals from a Swedish schizophrenia case-control
sample (50% cases and 50% controls).31
All samples were whole-exome sequenced at the Broad Institute
with the use of whole-blood DNA as previously described.9 One of
the driving forces in deriving a rigorous data-driven normalization
technique, which does not require explicit knowledge of how
systematic effects cause read depth to vary, was the fact that these
data had somewhat varying sequencing coverage and experi-
mental batches; this scenario is typical as workflows are frequently602 The American Journal of Human Genetics 91, 597–607, Octoberupdated. Indeed, sample batch was correlated with a few of the
highest variance principal components removed during normali-
zation (Figure S5). The use of human subjects for this research
was approved by an institutional review board.Comparison with Affymetrix SNP Microarray
CNV Calls
For the case-control data set, all samples were previously geno-
typed on Affymetrix 5.0 or 6.0 arrays and CNVs were called with
Birdsuite32 on the intensity data as previously described.31 The
trio samples were also run on the Affymetrix 6.0 platform, and
array-detectable de novo CNVs were called and validated as
recently described.7Results
To calibrate XHMM parameters, we used the family-based
data set of 90 schizophrenia trios to estimate HMM transi-
tion and emission parameters on a grid search (see Material
and Methods). We then examined a range of call quality-
score thresholds (Figure 2) and considered only those
CNV calls of two targets or more. As expected, the number
of rare (<5%) CNV events decreases as more stringent (SQ)
quality filtering is applied (Figure 2, left panel). For each
CNV discovered in a child, we used the genotyping quality
scores to detect de novo CNVs in a quantitative fashion,
i.e., by requiring high certainty that the child has a deletion
and the parents do not. That is, applying score filters
results in only a handful of trio offspring that have any
de novo CNVs, as expected given Mendelian inheritance
and a low mutation rate (Figure 2, middle panel). More-
over, when parental CNVs are genotyped in the child,
the median transmission rate from parent to child
converges to 50%, as expected from random Mendelian
segregation (Figure 2, right panel). We repeated these anal-
yses by limiting to shorter CNVs (<100 kb) and had almost
identical results, indicating our confidence in XHMM
CNV calls of various lengths. In addition to globally
ensuring CNV call quality, we note that of the three inde-
pendently validated array-based de novo CNV calls in
these 90 samples (overlapping exome targets),7 XHMM de-
tected two of these with high quality (Figures S7 and S8).
The remaining one overlaps only two exome targets, for
which we observe lower overall concordance rates with Af-
fymetrix (see below), but manual inspection indicates a
subthreshold de novo deletion that is observable only as
a result of the PCA normalization (Figure S9).
Next, we took the trio-calibrated parameters and applied
them to the set of 1,017 schizophrenia case-control
samples. Running XHMM yielded a total of 2,315 rare
(frequency < 1%, calculated by PLINK33) CNVs and a
median of two rare CNVs per individual (one deletion
and one duplication); over 80% of all CNV were <100 kb
(Figure S10). To corroborate our calls, we utilized similarly
rare, reliable (>100 kb) Birdsuite calls that were made on
these same samples with Affymetrix 6.0 arrays and
that overlap one or more exome targets (544 in total;5, 2012
Table 3. Sensitivity of XHMM to Affymetrix-Based Calls
t Exome
Targets
Affymetrix-Based
Calls Overlapping R t
Targets
XHMM
Sensitivity to
Affymetrix
Median
Affymetrix CNV
Length (kb)
1 544 367 (67%) 214
2 483 365 (76%) 218
3 452 357 (79%) 219
4 409 330 (81%) 202
5 362 309 (85%) 205
6 321 282 (88%) 232
8 288 260 (90%) 240
10 247 227 (92%) 259
Using the trio-calibrated XHMMquality scores (Figure 2), we applied XHMM to
a sample of 1,017 schizophrenia case-control samples and measured what
fraction of high-quality rare Affymetrix-based CNV calls (that overlap at least
t exome targets) are captured by the XHMM calls.Table S1). XHMM detected 67% of these, and this rate
increased to 85% for Affymetrix calls overlapping five or
more exome targets (Table 3); see Table S2 for separate
sensitivities to deletions and duplications. We conclude
from the case-control and trio sets that XHMM performs
well in detecting high-quality rare CNVs that span three
or more exons because of its sensitivity of 79% and its
high specificity corresponding to a 50% transmission rate
in trios.
We leveraged the resolution of exome sequencing to
detect CNV events that fall within a gene and disrupt
said gene by requiring high confidence of a copy-number
change within a single transcript; the XHMM CNV in
Figures S7 and S8 are examples of partial gene deletions.
We implement this search by thresholding on the
XHMM-estimated breakpoint quality metrics, LQ and
RQ. When searching the case-control sets, we detected
182 rare, high-quality disruptive deletions and signifi-
cantly greater burden in cases (rate of 0.22 versus 0.14 in
controls, p ¼ 0.007 according to PLINK33), suggesting
that gene-disruptive CNVsmight play a role in the etiology
of schizophrenia. In contrast, we observed no overall
enrichment of CNVs in general (either from exome
sequencing or the Affymetrix calls) in this n ¼ 1,017
subsample. As we continue our sequencing of this cohort,
we will systematically follow up on this result, which is
consistent with the hypothesis that disruptive events are
more likely to be pathogenic.16
While this manuscript was under review, the CoNIFER
method for detection of copy-number changes was pub-
lished.34 The depth-normalization approach in XHMM
and CoNIFER is similar; both effectively use the SVD
implementation of PCA to detect and remove large read-
depth variations due to non-CNV signals. However, the
methods significantly diverge thereafter in their use of
these normalized data. CoNIFER makes calls on the basis
of consecutive runs of at least three targets with valuesThe Americabove or below a hard threshold, whereas XHMM takes
advantage of the full power of HMMs to make and assess
the quality of the CNV calls. Moreover, we note the impor-
tant distinction between how the CoNIFER paper and the
present paper use the term ‘‘genotype.’’ In the former,
‘‘genotype’’ is used in the strict sense of determining abso-
lute copy number at common CNP loci, whereas the
‘‘statistical genotyping’’ performed by XHMM is actually
a probabilistic assessment (for a genomic interval) of the
copy-number states (here, diploid, deletion, or duplica-
tion) we consider given the observed read-depth data
across the exome. As in CoNIFER, hard copy-number calls
can bemade from these genotyping scores, althoughwe do
not discard these scores because they play an important
role in the analysis of the data. Our approach differentiates
between notmaking a call and actually declaring with high
certainty that the individual has diploid copy number.
The high sensitivity (79%–85% for CNVs overlapping
three to five targets; see Table 3) that we observed in detect-
ing rare chip-based CNVs by using XHMM is similar to the
estimate (between 76% and 84%) reported in the CoNIFER
paper. With this in mind, we sought to characterize the
differences between XHMM and CoNIFER and particularly
focused on the specificity of the call sets. We started by
comparing the overlap of the rare CNV calls made by the
two algorithms for the 90 schizophrenia trios (Figure 3
and Table 4). For the sake of comparison, we used the
same BWA-mapped reads as input to the two algorithms,
and we ran CoNIFER by using default parameters. A single
low-depth outlier sample that was removed by XHMMwas
also noted by the CoNIFER protocol. For the autosomes, we
used CoNIFER to remove six principal components, and
visual inspection of the singular values confirmed that
this was near the inflection point of the scree plots. Here,
we considered only those XHMMCNVs consisting of three
targets or more for an equal comparison with CoNIFER’s
behavior.
The main findings, which we detail below, are:
d CoNIFER calls possess a high rate of Mendelian viola-
tions, whereas XHMM statistical genotyping leads to
very few (Table 4).
d CoNIFER makes more calls than XHMM, whereas
XHMM provides quality scores to obtain calls with
higher confidence (Figure 3A).
d CoNIFER calls are longer than corresponding XHMM
calls (Figure 3B) and extend into additional genes.
Considering rare (<5% frequency) CNVs, CoNIFER
makes 30% more calls (n ¼ 2,206) than does XHMM
(n ¼ 1,691 raw [Q ¼ 0] calls) (Figure 3A). Going to
higher-quality XHMM calls (Q ¼ 60), 689 (68%) of the
XHMM calls have evidence from a CoNIFER call, whereas
these overlapping calls make up only 31% of the CoNIFER
calls. Thus, the quality scores we have developed serve as
an intrinsic mechanism for selectively obtaining these
reliable calls (with secondary ‘‘confirmation’’) and asan Journal of Human Genetics 91, 597–607, October 5, 2012 603
AB
Figure 3. Comparison of XHMM and CoNIFER CNV Calls
(A) Overlap between XHMM and CoNIFER rare (<5%) CNV calls made on the 90 schizophrenia trios, for which XHMM calls are filtered
at progressively higher quality filters (Q). Note that overlapping calls are counted as one event.
(B) Comparison of the properties of the XHMM Q ¼ 60 and CoNIFER CNV calls: genomic length of CNV (left panel), number of exome
targets (exons) in a CNV (middle panel), and the distance between consecutive exons in a CNV (right panel).a complement to successful filtering based on segmental
duplications or similar genomic features.34
We observed striking differences in the properties of the
XHMM (Q ¼ 60) and CoNIFER CNV sets in terms of size,
number of exons called, and distance between exons in
CNV calls (Figure 3B). We found that, overall, the CoNIFER
calls are longer than the XHMM calls (Figure 3B, left histo-
gram, mean of 82 kb versus 280 kb, t test p ¼ 4 3 1011).
However, although XHMM does have a higher proportion
of calls consisting of between three and five targets
(Figure 3B, center, first pair of bars), it is not the case that
the CoNIFER calls always include more exons—XHMM
makes relatively more calls of 21 targets or more. This
most likely results from the ability of the HMM caller to
effectively smooth out the normalized read-depth signal
and call some large CNVs spanning noisier genomic
regions. Notwithstanding, CoNIFER has a significant
tendency to include more distant targets within the same
CNV call, as measured by the distance between consecu-
tive exons called in a particular CNV (Figure 3B, right,
mean of 6 kb versus 23 kb, p ¼ 6 3 1013). These results
are consistent with the implementation of CoNIFER as
making calls across extreme-depth exome targets irrespec-
tive of their relative genomic distance. On the other hand,
XHMM conservatively requires additional evidence (i.e.,604 The American Journal of Human Genetics 91, 597–607, Octobermore extreme normalized read depth) to extend a CNV
call across larger genomic intervals (because parameter D
attenuates the transition probabilities as a function of
distance) while still smoothing out the signal by allowing
calls to sometimes extend across noisier regions.
Restricting the above analysis to the 689 high-quality
CNVs overlapping in the two call sets, we observed
similar significant differences between these intrinsic
CNV-call features. Moreover, whereas we noted above
that CoNIFER often seems to overextend CNV calls by
not regarding intertarget distance, it also inversely tends
to break up XHMM calls at a higher rate than XHMM
does with respect to CoNIFER calls (17 XHMM calls broken
up into two or more separate CoNIFER calls, but only
one CoNIFER call is split in two by XHMM). This presum-
ably results from the lack of CoNIFER smoothing that is
available to XHMM in the form of an HMM calling
procedure. For these CNVs overlapping between XHMM
and CoNIFER, we found the CoNIFER calls to have
a marked mean increase in CNV length (180 kb longer,
paired t test p ¼ 9 3 1015) and a mean of 3.9 more targets
(p ¼ 4 3 1015).
We then assessed how the above differences in CNV
sizes between XHMM and CoNIFER affect which genes
are implicated by a particular call. As an example, if one5, 2012
Table 4. Mendelian Inheritance Analysis for XHMM and CoNIFER
Median Number
of Child CNVs
Median Number
of De Novo CNVs
Proportion of Children with
One or More De Novo CNVs
Median
Transmission Rate
Hard Calls
XHMM (Q ¼ 60) 3 1 62% 33%
CoNIFER 8 3 91% 29%
CoNIFER (unique) 5 3 88% 23%
CoNIFER (XHMM overlap) 2 0 37% 43%
Statistical Genotyping
XHMM (Q ¼ 60) 3 0 13% 50%
From top to bottom, the high-quality XHMM call set, the CoNIFER set, the calls unique to CoNIFER, the overlap set between XHMM and CoNIFER, and the
statistical genotyping in XHMM were analyzed for Mendelian violations and inheritance patterns. See main text for details.considers the validated de novo CNVs overlapping
DLGAP1 (MIM 605445) (Figure S7) and EHMT1 (MIM
607001) (Figure S8), the CoNIFER calls seemingly over-
extend the XHMM and validated calls and overlap an
‘‘additional’’ gene in one case (for the DLGAP1 deletion).
Overall, comparing only calls with some overlap between
XHMM and CoNIFER, we found that the genes implicated
by both algorithms are copy-number variable in 7.2
exons on average, whereas the genes implicated by the
CoNIFER-unique part of the same CNV call include only
4.1 exons (p < 1016). This is consistent with our assess-
ment that it is critical to account for genomic distance in
callingCNVs so that a small number of targetswith a similar
read-depth trend in a neighboring gene do not artificially
extend a particular CNV call. We thus conclude that
compared with XHMM, CoNIFER might often add extra
targets (as well as extra genes with fewer supporting targets
in the CNV call) and that, overall, XHMMmight give more
accurate CNV breakpoints for its calls. We expect the reso-
lution of exome-based CNV breakpoints to be particularly
critical in: (1) gene-set enrichment analysis of genes hit
by CNVs, where the inclusion of false-positive genes will
decrease testing power by adding noise to the tests; and
(2) gene-disruption analysis, where it is especially impor-
tant to resolve the correct breakpoint in the CNV call, or
at least provide a measure of breakpoint quality (output
by XHMM as LQ and RQ), so that we can know when
a CNV is more likely to affect only part of a gene transcript.
Finally, Table 4 presents the results of Mendelian-inher-
itance analysis (counting putative de novo CNVs and the
fraction of CNVs transmitted from parent to child) for
various subsets of the calls. We found that CoNIFER makes
more de novo calls (91% of children with at least one de
novo call) and fewer transmitted parent calls (29%) than
the quality-filtered XHMM calls with hard genotyping
(33%). When the CoNIFER calls are split into those with
XHMM overlap and those without, the overlapping ones
have much better Mendelian metrics (only 37% of chil-
dren with a de novo and 43% transmission). It is important
to emphasize that both the CoNIFER and Q ¼ 60 XHMM
calls have Mendelian violations that result from the useThe Americof hard genotyping without the assessment of the actual
confidence of being diploid. On the other hand, statisti-
cally genotyping the XHMM calls results in a large
majority of trios that have no de novo CNV calls, but the
trios still maintain a median of 50% of parental CNV
that is transmitted to the children (these data are identical
to those in Figure 2 for Q ¼ 60). Thus, we conclude that
both quality filtering and statistical genotyping will play
an important role in constructing a prioritized list of a
smaller number of (de novo) CNV calls that we expect to
be experimentally validated.Discussion
In this paper, we present a tool (XHMM) to comprehen-
sively normalize sequencing coverage in large-scale exome
sequencing and use this rich information to discover CNVs
while providing quality metrics that indicate how strongly
the data support a particular CNV. We demonstrate that
XHMM has high specificity (few Mendelian violations in
trios) along with high sensitivity to reliable Affymetrix
calls. Using CNV-breakpoint quality metrics, the XHMM
framework also permits high-resolution discovery of
partial gene disruptions, a form of structural variation
potentially involved in disease pathology,16 and we ob-
served a possible burden of gene-disrupting deletions in
schizophrenia.
To use the XHMM suite for smaller-scale targeted
sequencing, themain limitations in decreasing the number
of targets or number of samples are a function of the
PCA normalization step, which will degrade in per-
formance because the read-depth aberrations (due to true
copy-number changes) of any single target or samplemight
be filtered out as ‘‘batch’’ effects. In addition, in order
to detect and remove underlying experimental artifact
(e.g., GC bias), the PCA will need to see a nontrivial subset
of samples or targets with that particular trend. Thus, in
practice, we would recommend using XHMM with on the
order of at least 1,000 targeted regions and 50 (unrelated)
samples. For the case of related samples, we propose usingan Journal of Human Genetics 91, 597–607, October 5, 2012 605
principal components derived from larger sets of samples
sequenced contemporaneously under similar conditions
so that familial CNVs do not dominate the read-depth
signal and are not picked up by PCA. Thus, we explicitly
chose a parameterization of read-depth normalization
(Equation 1) so that the principal components (ci) need
not be derived from the matrix R to be normalized, as
long as they are defined for the same target set.
In terms of coverage, the important point is that the
dynamic range of the read-depth signal be large enough
that decreases can be assigned to underlying deletions
and increases to duplications. Thus, although the
sequencing coverage for the samples here was at least
1003 on average, XHMM could be applied with lower
mean sequencing coverage (say, 503), as long as the
observed coverages do not essentially degenerate into a
discrete all-or-none value. XHMM could also potentially
be adapted in the context of whole-genome sequencing,
e.g., by the division of the genome into ‘‘pseudotargets’’
with the use of a sliding-window approach.13 For
simplicity, XHMM does not explicitly consider homozy-
gous deletions or duplications (or copy number above 3),
although we expect such events to be correctly called as
copy-number variable. These can be modeled by the
augmentation of the HMM with states corresponding to
these copy numbers. Also, although XHMM can work
with sex chromosomes, we performed all analyses herein
on the autosomes to limit cryptic sex-specific effects, for
which additional normalization might be required.
In summary, the distinguishing features of XHMM are:
(1) efficient data-driven whole-exome read-depth normali-
zation with the use of PCA for thousands of individuals (it
does not rely on a single reference sample or any prede-
fined notions of read-depth confounders), (2) incorpora-
tion of genomic distance into the calling procedure for
well-calibrated CNV lengths, (3) use of a HMM for
smoothing over noisy regions and taking into account
exome-wide CNV rates, (4) HMM-based quality scores for
filtering good calls from bad calls, and (5) using these
quality scores and breakpoint metrics for statistically
genotyping discovered CNVs in other individuals and
detecting de novo and gene-disrupting events. We have
demonstrated that these features endow XHMM with
superior performance in the analysis of real data sets, and
we expect exome-based CNV analysis to be a useful
complement to array-based approaches because of their
differential strengths and biases.Supplemental Data
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